Abstract Air pollution constitutes an important factor for asthma aggravation, and there is increased concern about respiratory health effects of common air pollutants.The purpose of this study was to examine how exposure to a high ambient concentration nitrogen dioxide (NO 2 ) prior to a bronchial allergen challenge modulated the inflammatory response in the bronchi. Thirteen subjects with mild asthma and allergy were exposed at rest to either purified air or 500 mg Â m À3 NO 2 for 30 min, followed 4 h later by an allergen inhalation challenge.The exposures (NO 2 or air) were performed in random order and at least 4 weeks apart. Lung function during NO 2 /air exposure and allergen challenge was measured by plethysmography, and then hourly by portable spirometry after exposures. Subjective symptoms were recorded during and after exposure. Bronchoscopy with bronchial wash (BW) and bronchoalveolar lavage (BAL) was performed 19 h after allergen challenge. NO 2 +allergen enhanced the percentage of neutrophils in both BW and BAL compared to air+allergen (BW19 vs.11, P¼0.05;BAL 3 vs.1, P¼0.02 medianvalues).The levels of eosinophil cationicprotein (ECP) in BW was higher after NO 2 +allergen compared to air+allergen (9.0 vs.3.6 mg/l; P¼0.02, medianvalues).There was no NO 2-associated effect on symptoms or pulmonary function.These data suggestthat ambient NO 2 can enhance allergic inflammatory reaction in the airways without causing symptoms or pulmonary dysfunction. r
INTRODUCTION
Nitrogen dioxide (NO 2 ), a gas produced by combustion, is a common environmental air pollutant. The main outdoor sources are vehicular tra⁄c, and indoor sources are gas appliances.
Individuals with asthma are more sensitive to NO 2 exposure than healthy subjects, according to results from controlled human-exposure studies. Short exposures to high ambient levels of NO 2 can increase exercise-induced bronchospasm (1) and the bronchial responsiveness to inhaled nonspeci¢c agents in asthmatics (2) . The main effect of NO 2 in these studies was on bronchial responsiveness, with pulmonary function not being affected at those NO 2 doses. NO 2 can also enhance the asthmatic response to inhaled allergen (3, 4) . This amplifying e¡ect on the asthmatic response has also been reported after repeated exposure to NO 2 in combination with low, non symptom-causing doses of allergen (5) , suggesting that NO 2 may exert this e¡ect commonly on asthma patients.
The mechanisms for NO 2 's enhancing e¡ect on the asthmatic reaction to allergen appear to be related to an increased in£ammatory reaction in the bronchi. The extent to which in£ammatory cells and mediators are linked to this response is not well understood. Exposure to high doses of NO 2 alone (30007 000 mg Â m À3 ), which occurs in certain industries and mines, has been shown to increase the number of neutrophils in bronchial lavage £uid in healthy subjects the ¢rst hours after exposure (6^8), while exposure to ambient levels of NO 2 (o1000 mgm
À3
) does not seem to a¡ect cell numbers in bronchial lavage £uid in humans (6) .
Bronchial allergen challenge, on the other hand, gives an in£ammatory response which is characterized in bronchoalvedar lavage (BAL) £uid by eosinophilia, which is noted as soon as 2^4 h after challenge and persisting up to 24 h post-challenge (9) . Occasionally, neutrophilia occurs in the bronchi some hours after allergen challenge, but this usually subsides with normal values noted 24 h later (9) .
These results suggest that the neutrophil and eosinophil constitute the prime e¡ector cells in NO 2 and allergen-induced airway in£ammatory reaction. However, to date there has been no experimental examination of the impact of a combination of NO 2 and allergen on the in£ammatory response in the bronchi, though combination NO 2 and allergen exposure is likely to occur in asthma patients.
We hypothesized that NO 2 would enhance the airway in£ammatory response of eosinophil and neutrophil granulocytes and mast cells to allergen inhalation.
We aimed to test this hypothesis in an exposure study, with short-term exposure to NO 2 and a subsequent allergen challenge.
METHODS
Subjects (Table 1) Thirteen adult subjects with mild asthma and allergy to birch or timothy pollen participated in the study. There were six men and seven women; the mean age was 29 years in the age range 23^39 years. All were nonsmokers.
At a pre-inclusion visit at least 4 weeks before the study started, a seasonal allergy to either birch or timothy pollen was con¢rmed by positive skin prick test (43 mm). The diagnosis of extrinsic asthma was based on a typical history of attacks of dyspnoea during the pollen season and a positive bronchial challenge with the relevant allergen. Six subjects had a late phase reaction de¢ned as =15% decline in forced expiratory volume 14  284  256  110  11  F  25  N  8  T  3.03  88  12  803  423  220  12  F  26  N  1  T  3.09  91  8  326  55  19  13  F  27  N  8  T  4  109  14  699  163  69  Mean  28  14  3.75  97  Std  5  10  0.46  11  Median  9  326  256  110  25th percentile  129  47  18  75th percentile  526  1286  550 Note: F¼female, M¼male; N¼never smoker, E¼ex smoker;T¼timothy,B¼birch.*Skin prick test o3 mm¼positive reaction.
w Provocative dose of histamine causing a100% increase in speci¢c airway resistance. z Provocative dose of allergen causing a100% increase in speci¢c airway resistance. } Inhaled allergen dose after NO 2 /air. in 1s (FEV 1) 3^10 h after the allergen challenge. Airway hyperresponsiveness was also con¢rmed by a positive histamine inhalation test. Upon inclusion, the lung function expressed as FEV 1 was 97711% of predicted (mean7SD; range 85^119%). All subjects were treated with inhaled b 2 -agonist as needed, and 12 subjects were treated with inhaled steroids only during the pollen season, though none during the study period.
All subjects had a normal serum CRP-value on the ¢rst exposure day as an indication of no ongoing bacterial infection.
The study was approved by the Ethics Committee at Huddinge University Hospital.
Study design
All subjects were exposed for 30 min at rest in an exposure chamber to ¢ltered air or to a concentration of 500 mg Â m À3 (260 ppb) NO 2 on two separate occasions at least 4 weeks apart.The order of exposure was randomized (7 ¢rst NO 2 , 6 ¢rst air). Four hours after exposure, a bronchial challenge with an individually ¢xed dose of birch or timothy pollen was performed.The time interval of 4 h was based on an established protocol from previous studies (4) .The inhaled allergen dose was 40% of the dose estimated to cause100% increase in speci¢c airway resistance at the screening visit, based on a previous study with NO 2 and allergen from our laboratory (5). Bronchoscopy with bronchial wash (BW) and bronchoalveolar lavage (BAL) was performed 19 h after the allergen challenge.
Each experiment had the following design: after arrival to the laboratory in the morning, the subject rested for 15 min. Speci¢c airway resistance (SR aw ) and thoracic gas volume (TGV) were measured with a whole-body plethysmograph, and FEV 1 with a portable spirometer. The subject then rested 10 min more before entering the exposure chamber. During the 30 min of exposure to air/NO 2 , lung function (SR aw , TGV) was measured after 4, 15, and 30 min of exposure, and an interview concerning symptoms was conducted after 3 and 26 min according to a standardized questionnaire.
After exposure, FEV 1 was measured hourly using a portable spirometer. Before and after the allergen inhalation, lung function was again measured by plethysmography. After the allergen inhalation, the subject went home and continued to measure FEV 1 hourly until10 p.m.
The subjects were instructed to use an inhaled bronchodilator if necessary and to keep a record of symptoms and medication.
The exposure types were blinded to the subjects and the investigators analysing the bronchial lavage £uid and the results from the portable computerized spirometer.
Whole-body plethysmography
Airway resistance (SR aw ) and TGV were measured in a constant volume body plethysmograph (Model 2000 TB; Cardio-pulmonary Instruments, Houston, TX, U.S.A.) according to the method of Du Bois and colleagues (10, 11) .
The gas £ow/box-pressure slopes were measured between gas £ow +0.5 and À0.5 l Â s À1 (expiration^in-spiration) as a mean of two or three measured slopes. The mouth/box-pressure slopes were measured between the endpoints, again as the mean of two to three curves.
Spirometry
The measurements of FEV 1 were made using a portable computerized spirometer (Diary Card spirometer, Micromedical Ltd. Chatham, Kent, U.K.) and the data later downloaded to a computer.
The maximal fall in FEV 1 from before allergen challenge to 3^10 h after allergen challenge, as well as the average fall in FEV 1 during this period, was used to measure the asthmatic reaction during the late phase.
Results for FEV 1 are provided in litres, and statistical evaluation of e¡ects are normalized to each individual's best FEV 1 .
Histamine bronchial challenge
Histamine provocation tests were performed by using an automatic inhalation-synchronized dosimeter jet nebulizer (Spira Elektro 2; Respiratory Care Center, Hameenlinna, Finland) with an adjustable aerosol delivery time according to a previously described method (5, 12) . SR aw and TGV were measured 3 min after each dose.The provocative dose (PDSR aw 100% ) was calculated by linear interpolation on a logarithmic scale.
Allergen bronchial challenge
The allergen challenge at the screening visit and during the study was performed with the same dosimeter jet nebulizer (Spira Elektro 2) as for histamine inhalation. Standardized and freeze-dried birch or timothy allergen extracts (Aquagen, Alk,Copenhagen, Denmark) were diluted and used at a maximum of four concentrations: 1000, 4000, 16 000 and 64 000 (Standardized Quality) SQ allergen units ml
À1
.The nebulizer was set to nebulize for 0.5 s giving an output of 7.1 ml breath
. At each concentration, two and four breaths could be taken, and if needed even followed by eight and16 breaths at the highest concentration providing doses from 14 to 7040 SQ allergen units. SR aw and TGV were measured 15 min after each dose of allergen. The challenge proceeded until a 100% increase in SR aw was reached. PDSR aw 100% for allergen was calculated by linear interpolation on a logarithmic scale.
The inhaled allergen dose in the study was set to 40% of the PDSR aw 100% at the screening visit, or, when this was impossible to administer for practical reasons, the dose was as above (seeTable 1). FEV 1 and SR aw were recorded immediately before and 15 min after the single dose of allergen was inhaled.
Blood samples
Blood samples were obtained on two occasions; 1 day prior to exposure for CRP analyses and 1 day prior to BAL for analysis of albumin.
Questionnaire
After 3 and 26 min of exposure in the chamber, the subjects were asked 16 questions concerning respiratory symptoms and perceptions of discomfort (i.e. tight chest, cough, headache, odour), reporting symptoms on a scale of 0 (none)^7 (maximal). Throughout the day, and then on the following morning, the subjects kept a self-administered daily record of bronchodilator medication and symptoms from bronchi, nose, and eyes.
Gas dilution and exposure system NO 2 from a gas bottle (Alfax, approximately 8.000 mg Â m À3 NO 2) was diluted in two steps to a ¢nal concentration of approximately 500 mg m À3 NO 2 and then was fed into the exposure chamber (volume 7 m
À3
). The gas dilution and exposure system is presented in detail elsewhere (13) .
Chemical analyses
NO 2 concentrations in the exposure chamber were measured with a chemiluminescence instrument (Model 8440 Nitrogen Oxides Analyser; Monitor Laboratories, Englewood,CO,U.S.A.).For calibration, an NO 2 permeation tube and NO calibration gas (Model 8500 Calibrator; Monitor Laboratories, Englewood, CO, U.S.A.; AGA Special gas, 100 ppm NO) was used. A calibration procedure was performed daily.
The subjects' individual exposure to NO 2 outside the chamber during the study days was measured with a personal passive (¢lter badge) sampler (Toyo Roshi Kaisha, Ltd, Tokyo, Japan) (14) .
Exposure data NO 2 concentrations in the exposure chamber were measured in the breathing zone of the subject. The concentration was 493710; 468^505 mg Â m À3 (average of mean concentrations during 30 min7SD; range). During exposure to ¢ltered air, the NO 2 concentration was below 10 mg Â m
À3
. The temperature in the exposure chamber was 24.070.81C (mean7SD) during air and 24.470.81C during NO 2 exposure. The corresponding values for relative humidity were 39712% (n¼11) and 3678% (n¼12).The exposure to NO 2 in ambient air outside the chamber measured with the personal sampler was 1879 mg Â m À3 (23 h mean7SD, 9 a.m. day1^8 a.m. day 2) during the NO 2 exposure and 25711 mg Â m À3 during the air exposure, which was signi¢cantly di¡erent (P¼0.046).
Bronchoscopy and bronchoalveolar lavage
All bronchoscopies were done between 8 and 9 a.m. by the same bronchoscopist (CB). VC and FEV 1 were measured before the procedure. Fibreoptic bronchoscopy was performed after premedication with morphine hydrochloride and scopolamine hydrobromide (Mor¢n-scopolamin s Pharmacia, Uppsala, Sweden). Fifteen minutes before the bronchoscopy, all subjects inhaled 0.4 mg salbutamol. Local anaesthesia was administered before and during the procedure with lidocaine (Xylocain s , Astra, S˛dertÌlje, Sweden). The Olympus B1-IT 20 (Olympus Optical Company, Tokyo, Japan) bronchoscope was introduced through the nose or the mouth into the lung, and wedged in a subsegmental bronchus of the middle lobe. Lavage was performed using one aliquot of 20 ml, and three aliquots of 50 ml sterile warm 0.9% NaCl, instilled into the middle lobe subsegment. The £uid was gently aspirated after each aliquot and collected in propylene tubes. The ¢rst 20 ml that was instilled, the BW, was collected separately from the remaining 150 ml, the BAL.
Sample processing
The lavage £uid was ¢ltered through a Dacron net (Millipore, Cork, Ireland). Cells were pelleted by centrifugation at 41C, 400 g for 10 min, and the supernatants were stored at À701C after an additional centrifugation at 41C, 600 g for 10 min.
The cell pellets were resuspended in Hepes bu¡er (RPMI). The total number of cells was counted in a Bˇr-ker chamber, and their viability was tested by the exclusion of trypane blue. Slides for di¡erential counts were prepared by cytocentrifugation at 500 rpm for 3 min (Cytospin 3 Shandon, Southern Products Ltd., and Runcorn, England). Slides were stained with May-Grˇnwald Giemsa, and 500 cells were counted. Mast cells were stained with acid toluidine blue and counterstained with Mayer Ł s acid haematoxylin.
Analyses of soluble mediators
Analyses of soluble mediators were performed in cell free BW and BAL £uids .The £uids were distributed in portions and stored at À701C until analysed.
ECP levels were measured with a £uoroimmunoassay, Pharmacia ECP Cap System FEIA, (Pharmacia & Upjohn, Uppsala, Sweden), with a detection limit o2 mg/l.
MPO levels were measured with a competitive RIA (Pharmacia & Upjohn), which had a detection limit of o8 mgml
À1
. In this assay, MPO competes with a ¢xed amount of 125 I labelled MPO for the binding sites of speci¢c antibodies.
The levels of human IL-5, IL-8, eotaxin, and soluble-ICAM-1 were measured by ELISA technique using Quantikine immunoassays (R&D Systems, Inc, Minneapolis, MN, U.S.A.). According to the manufacturer, the minimum detectable concentrations for substances were IL-5 3.0 pg/ml, eotaxin 5.0 pg ml
, IL-8 10 pg ml
, and s-ICAM-1 0.35 ng ml 
RESULTS
Speci¢c airway resistance (SR aw ), and thoracic gas volume (TGV) ( 
Subjective complaints
When the subjects were interviewed during exposure concerning subjective complaints, no di¡erence between air and NO 2 exposure could be detected except for a slight increase in sense of anxiety and odour after 4 min of exposure to NO 2 Cell parameters in BW and BAL £uid (Table 4 and Fig. 1) There was a signi¢cant decrease in the recovered volumes of BAL £uid after NO 2 +allergen (P¼0.03). The median values of the recovered BW and BAL volumes after air+allergen exposure were 9 ml [ (Interquartile range (IQR) 7^10 ml)] and 105 ml (IQR: 101^109 ml), respectively. After NO 2 +allergen exposure, the corresponding ¢gures were 8 ml (IQR: 8^10 ml) and 93 ml (IQR: 71^105 ml).
The cell viability after NO 2 +allergen was unchanged in BAL, but decreased in the BW after NO 2 +allergen exposure (75 vs. 47%; P¼0.01, data not shown).
In the bronchoalveolar portion, both the total cell and macrophage concentrations decreased after NO 2 The numbers of eosinophils and mast cells for the two exposures were not di¡erent. (Table 5) ECP levels increased signi¢cantly in the bronchial portion (BW 3.6 vs. 9 mg/l; P¼0.02) after NO 2 +allergen, but not in the bronchoalveolar portion.There were no significant di¡erences in IL-8, IL-5, and sICAM-1 levels between NO 2 +allergen and air+allergen, neither in BW nor in BAL. Eotaxin and MPO concentrations in BW were consistently below detection levels.There were no signi¢cant di¡erences between NO 2 +allergen and air+-allergen in albumin levels in lavage £uid (BW; 9 vs. 9; BAL; 27 vs. 28 mgl 
Soluble mediators and albumin

Correlation between cell counts and ECP, IL-8, and IL-5
The neutrophil counts were associated with IL-8 levels (r¼0.59, P¼0.04) in BAL, but not in BW, and with ECP levels in both BAL and BW (r¼0.77, P¼0.01 and r¼0.60, P¼0.03, respectively).
The eosinophil counts in BW were associated with IL-8 levels (r=0.68, P¼0.01).The eosinophil counts in BAL were correlated to the ECP levels (r¼0.57, P¼0.04) and ECP levels correlated with IL-5 levels (r¼0.79, P¼0.001) in BAL.
DISCUSSION
The novel ¢nding in this study is that exposure to an ambient level of NO 2 , in the dose tested, enhanced subsequent allergen-induced in£ammatory reaction in the bronchi, as demonstrated by enhanced number of recruited neutrophils and levels of ECP. These in£amma-tory changes were not accompanied by any changes in pulmonary function or subjective symptoms.
Air pollution is generally recognized as a signi¢cant factor for asthma aggravation, and NO 2 exposure alone has been linked to increased asthmatic symptoms and enhanced bronchial responsiveness to both allergen and nonspeci¢c agents (15) . However, the understanding of mechanisms for potential synergistic actions between exposure to air pollution and allergen is incomplete. NO 2 +allergen caused decreased cell viability in BW in the current study.The cell viability in BW is typically not a¡ected by allergen challenge (16, 17) or NO 2 exposure (7, 18) . It is theoretically possible that the combined exposure to NO 2 and allergen leads to an increased release of cytotoxic substances in the bronchi. Since neither separate exposure to NO 2 nor allergen have been thought to cause such e¡ect, and no previous study on combined exposure to NO 2 and allergen has been reported, these ¢ndings need to be corroborated before an e¡ect of combined exposure can be determined with certainty.
The enhancement of neutrophils in the lower airways after exposure to NO 2 was an important ¢nding in the current study.There are no published data on the cell response in BAL after exposure to NO 2 in asthmatic subjects at a comparable time after exposure. However, NO 2 has not earlier been found to increase neutrophils in BAL in asthmatics immediately after exposure (19) . Normal subjects exposed to NO 2 did not show any change in neutrophil numbers in BW or BAL £uid at a comparable time (24 h after exposure), even though the concentrations were six-and15-fold, respectively, higher than that used in the current study (20, 21) . The levels of neutrophils in BW and BAL after air+allergen in the present study were similar to those reported in untreated normal subjects (22) and after NO 2 +allergen an about two-fold increase was seen. Allergen bronchial challenge per se caused no increase in neutrophils in asthmatics 24 h after challenge, although a transient increase of neutrophils in BAL £uid could be observed 2^4 h after allergen inhalation (9) .This indicates that neither exposure to low levels of NO 2 alone nor allergen alone induces a late airway neutrophilia, which was observed in this study after combined exposure to NO 2 and a low dose of allergen. The potentiating e¡ect of NO 2 on the neutrophilic response was relatively mild in this study. However, we cannot rule out the possibility that this potentiating effect of NO 2 could be even more pronounced when a higher allergen dose is chosen.
The quantity of MPO in both BAL and BW did not reach detectable levels by NO 2 , suggesting that the neutrophils were not signi¢cantly activated, in terms of degranulation. An increase in MPO has been associated with an increase of neutrophils in some NO 2 studies (23), but not in others (24) . However, since MPO was not detected after the exposures in this study, the possibility that methodological di¡erences exist between our experimental settings and those cited led to di¡erences in observations which cannot be excluded. There is increasing evidence that neutrophils play a role in asthma and especially in severe persistent asthma (25) , during exacerbations of asthma (26) , in status asthmaticus (27) , and in fatal asthma of sudden onset (28) . The fact that NO 2 exposure, even at a low concentration, promotes a neutrophilic type of in£ammation in patients with allergic asthma might therefore be of potential clinical importance.
Although the mean levels of IL-8 were not a¡ected in the current study, a signi¢cant overall correlation was seen between the number of neutrophils and IL-8 in BAL. This ¢nding suggests that chemotactic signalling for further recruitment of neutrophils was still occurring 19 h after allergen challenge in this NO 2^a llergen exposure model.
The levels of ECP after NO 2 +allergen increased significantly in BW, and a tendency towards a similar e¡ect was seen also in BAL. These ¢ndings support a previous observation that NO 2 increased the ECP levels in nasal lavage £uid after nasal allergen challenge (29) . The ECP level in BW after air+allergen was about one-third of that seen 24 h after challenge with a three-fold greater allergen dose (16) . After NO 2 + allergen, the ECP in BW increased three-fold and reached a level comparable to that reported after the higher allergen dose. It is noteworthy that in the current study, the levels of ECP increased although the numbers of eosinophils in BW were unchanged. One possible explanation of this di¡er-ence in ECP and eosinophil response might be a selective e¡ect on degranulation, but not on cell recruitment, after NO 2 exposure. Another contributing explanation is that ECP in BAL £uid origins from both bronchial and submucosal eosinophils, though their relative contribution remains unknown. A less likely explanation is that ECP is produced by other cells, since this possible noneosinophil ECP contribution to the overall ECP levels is not known (30) . NO 2 did not a¡ect the asthmatic reaction to inhaled allergen measured as changes in FEV 1 in the current study, in contrast to what has been seen in several previous studies (3^5). The NO 2 exposure dose has been the same in two of these studies. However, two factors di¡er: the individual exposure to NO 2 outside the chamber and the dose of allergen. The personal exposure to NO 2 in ambient air (outside the chamber) during the study day happened to be higher after air than after NO 2 in the current study. This reduced the di¡erence in NO 2 exposure between the NO 2 and the control experiment settings and might thereby have reduced the probability to detect the e¡ect on lung function related to NO 2 exposure in the chamber. The allergen doses in the studies in which NO 2 a¡ected lung function after allergen provocation were 10 and 100%, respectively, of PDSR aw 100% (4, 5) . In the current study, the dose of allergen was intermediate, 40% of PDSR aw 100% . If this di¡erence in allergen dose explains the di¡erent response in pulmonary function, it would imply that the NO 2 -induced enhancement of the asthmatic reaction to inhaled allergen is not linearly related to the allergen dose.
To conclude, combined exposure to ambient levels of NO 2 and allergen was followed by a late increase in numbers of neutrophils, which di¡ers from what has been reported after separate exposure to allergen or NO 2 . Moreover, NO 2 +allergen was followed by higher ECP levels in the bronchi than after air + allergen. Present data focus on subclinical in£ammatory reactions that may occur due to the synergistic action of an air pollutant and allergen, a situation that may frequently occur in daily life. The clinical impact of the results needs to be evaluated in future studies to fully delineate the long-term e¡ect of NO 2 exposure in asthma disease.
